Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora. (April 2023)

• Record Type: Journal Article
• Authors: Hao, Han; Li, Zhu; Qiao, Shi-yang; Qi, Yu; Xu, Xiao-ying; Si, Jia-yi; Liu, Yi-hai; Chang, Lei; Shi, Yi-fan; Xu, Biao; Wei, Zhong-hai; Kang, Li-na
• Is Part Of: Atherosclerosis. Volume 371(2023)
• Page Start: 32
• Page End: 40
• Publication Date: 2023-04
• Subjects: SGLT2i -- ApoE−/− -- Atherosclerosis -- Intestinal flora; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2023.03.011
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) has been reported to attenuate atherosclerosis. Further, it has been suggested that intestinal flora influences atherosclerosis progression. Herein we aimed to investigate whether SGLT2i can alleviate atherosclerosis through intestinal flora. Methods: Six-week-old male ApoE −/− mice fed a high-fat diet were gavaged either empagliflozin (SGLT2i group, n = 9) or saline (Ctrl group, n = 6) for 12 weeks. Feces were collected from both groups at the end of the experiment for fecal microbiota transplantation (FMT). Another 12 six-week-old male ApoE −/− mice were fed a high-fat diet and received FMT with feces either from SGLT2i (FMT-SGLT2i group, n = 6) or from Ctrl (FMT-Ctrl group, n = 6) groups. Blood, tissue, and fecal samples were collected for subsequent analyses. Results: In comparison with Ctrl group, atherosclerosis was less severe in the SGLT2i group ( p < 0.0001), and the richness of probiotic, such as f_Coriobacteriaceae, f_S24-7, f_Lachnospiraceae, and f_Adlercreutzia, was higher in feces. Besides, empagliflozin resulted in a significant reduction in the inflammatory response and altered intestinal flora metabolism. Interestingly, compared with FMT-Ctrl, FMT-SGLT2i also showed a reduction in atherosclerosis and systemic inflammatory response, as well as changes in the component of intestinal flora and pertinent metabolites similar to SGLT2i group. Conclusions: Empagliflozin seems to mitigate atherosclerosis partly by regulating intestinal microbiota, and this anti-atherosclerotic effect can be transferred through intestinal flora transplantation. Graphical abstract: Image 1 Highlights: Empagliflozin improves atherosclerosis to some extent by affecting intestinal bacteria. The benefits of Empagliflozin can be delivered through the intestinal flora. It is a novel thought that more drugs that have been used may act in part by influencing intestinal flora.